D. Longley

Oncology · 2005

A researcher in the Science corpus: 1 paper; trusts 6 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom D. Longley trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. Lewis C. Cantley
  2. Karen H. Vousden
  3. A. Baldwin
  4. Michael O. Hengartner
  5. A. Ashkenazi
  6. M. Karin
  7. Hua Yu
  8. G. Salvesen
  9. M. Jordan
  10. Michael M. Gottesman

Who trusts D. Longley overall

  1. M. Nedeljković
  2. Xiumin Wu

Papers from D. Longley's perspective

Ordered by how strongly the researchers D. Longley trusts endorse each paper. Same corpus, a different order for every researcher.

  1. The phosphoinositide 3-kinase pathway. (Science)
  2. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. (Clinical Cancer Research)
  3. Oncogenic kinase signalling (Nature)
  4. The STATs of cancer — new molecular targets come of age (Nature Reviews. Cancer)
  5. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. (Journal of Clinical Oncology)
  6. The protein kinase B/Akt signalling pathway in human malignancy. (Cellular Signalling)
  7. Role of BAX in the apoptotic response to anticancer agents. (Science)
  8. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. (Clinical Cancer Research)
  9. The biochemistry of apoptosis (Nature)
  10. Targeting death and decoy receptors of the tumour-necrosis factor superfamily (Nature Reviews. Cancer)

Their papers